Sven Rohmann
Interim Chief Executive Officer (also Member of the Board)

Born: 1962
Share holdings: –

Sven Rohmann has been the CEO of the two German biotech companies, BioVisioN and Ganymed Pharmaceuticals. He has also held senior managerial positions within Novartis and Merck-Serono. He spent 10 years at Merck-Serono, which provided him with a strong foothold in the pharmaceutical industry. His career exposed him to pre-clinical, clinical development as well as marketing, business and corporate development. During his tenure at Merck-Serono he headed the establishment of Merck Oncology. Moreover, he has been the Chairman of the Board in Helix BioPharma Corp and ImVisioN and Chief Medical Officer (CMO) of two companies in Austria and USA.

Dr. Rohmann’s unique combination of scientific, pharma, biotech and venture knowledge, an extensive network of contacts among health care providers and research administrators, a thorough knowledge of global research & development as well as EMA/FDA regulatory policies, and a significant experience in M&A and partnering, makes him one of the leading experts in innovation management, value building & capturing.

Anette Sjödin
Chief Business Officer and deputy CEO

Born: 1964
Share holdings: –

Anette Sjödin possesses more than 25 years of experience in the Life Science sector. She is a biochemist with many years of global experience including senior positions in marketing, project management and business development. Her most recent position was in business development at Nestlé Skin Health where she has worked internationally with in- and out licensing and was responsible for strategic alliances.

Mikael Asp
Chief Technical Officer

Born: 1962
Share holdings: 8,020 shares personally

Mikael has a Master of Science in Chemical Engineering and has 30 years of experience from several companies within the international pharmaceutical industry in research and development, production, quality assurance and as Qualified Person (QP).

Nina Heldring
Acting Chief Medical Officer

Born: 1968
Share holdings: –

Nina Heldring, PhD, has 20 years of experience in preclinical and clinical medical research from well-known academic institutes such as Cornell University in the US and Karolinska Institutet but also the pharmaceutical industry. She started as Head of Clinical Development at Oasmia in 2016 and has led the work on pharmacovigilance and clinical trials. Nina took up her new position as Acting Chief Medical Officer in July 2019.

Reinhard Koenig
General Manager, US & Canada (acting)

Born: 1960
Share holdings:

Reinhard Koenig has more than 30 years of pharma and biotechnology experience. He has extensive experience of leading positions within global pharmaceutical companies. Previous companies include Genentech, Boehringer Mannheim and Piramal Critical Care.

Michael af Winklerfelt
Chief Financial Officer

Born: 1972
Share holdings: –

Michael af Winklerfelt has more than 15 years of experience from senior finance roles in leading international companies. He worked for ten years in China for the Atlas Copco Group and most recently spent three years in the United States in the medical device field. He has an MBA, an M.Sc. in Economics and Business and an unfinished B.A. in Chinese.

Neil Yman
GM Europe & Russia

Born: 1969
Share holdings: 1,000 shares

Neil Yman has over 17 years of pharma and oncology experience in positions with Pierre Fabre, Novartis, GSK and Roche. He has extensive experience of leading positions within global pharmaceutical companies.